Mantle Cell Lymphoma | Clinical

Ibrutinib or R-BAC Prolong PFS2 in Relapsed/Refractory Mantle Cell Lymphoma

May 05, 2021

Patients with mantle cell lymphoma treated with second-line ibrutinib or the R-BAC regimen experienced improvement in progression-free survival 2 compared with treatment on rituximab and bendamustine and other regimens, according to findings from the international, retrospective MANTLE-FIRST study.

Preclinical Research Shows Potential for EZH1/2 Dual Inhibitor In Relapsed/Refractory MCL

April 19, 2021

A new report on ibrutinib-resistant mantle cell lymphoma patient-derived xenograft mouse models shows the potential benefit of the EZH1/2 inhibitor OR-S1, as other similar inhibitors have shown benefit in patients with hematologic cancers.

Further Promise for CAR T-cell Therapy Use in R/R MCL Observed with Liso-Cel

March 24, 2021

In an interview with Targeted Oncology, Maria Lia Palomba, MD, a hematologic oncologist at Memorial Sloan Kettering Cancer Center, discussed the efficacy and safety of liso-cel in patients with R/R MCL as observed in the phase 1 TRANSCEND NHL 001 study.

The Efficacy of Ibrutinib Plus Venetoclax for the Treatment of R/R MCL

February 18, 2021

Constantine Tam, MD, discuses the outcomes of the phase 3 Sympatico Study, which evaluated the safety and efficacy of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for the treatment of relapsed or refractory mantle cell lymphoma compared to monotherapy.